Departments of Ophthalmology (YMP, JLB, PSS, VSP), Neurology (YMP, JLB, PSS, VSP), and Neurosurgery (PSS), University of Colorado School of Medicine, Aurora, Colorado; and Programs in Neuroscience and Immunology (JLB), University of Colorado School of Medicine, Aurora, Colorado.
J Neuroophthalmol. 2020 Sep;40(3):305-314. doi: 10.1097/WNO.0000000000001016.
The initiation and continuation of immune-based therapies to treat and prevent complications of inflammatory neuro-ophthalmologic disorders during the 2019 novel coronavirus (COVID-19) pandemic is the subject of considerable debate. In each case, a treatment decision must be reached based on best clinical practices for the disorder, patient comorbidities, the current state of knowledge about the pathogenesis and infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the utilization of hospital and community resources. Unfortunately, the evidence needed to standardize the decision-making process for each neuro-ophthalmologic disorder is currently absent and is likely to require months or years to develop based on the accrual of robust international data sets. In this article, we review the current understanding of SARS-CoV-2 and COVID-19 complications to provide a framework for approaching the treatment of inflammatory neuro-ophthalmic disorders during the COVID-19 viral pandemic.
在 2019 年新型冠状病毒（COVID-19）大流行期间，启动和继续进行免疫治疗以治疗和预防炎症性神经眼科学疾病的并发症是一个备受争议的话题。在每种情况下，都必须根据疾病的最佳临床实践、患者合并症、对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）发病机制和传染性的现有知识以及医院和社区资源的利用情况来做出治疗决策。不幸的是，目前缺乏标准化每个神经眼科学疾病决策过程所需的证据，并且可能需要根据积累的强大国际数据集花费数月或数年的时间才能开发出来。在本文中，我们回顾了对 SARS-CoV-2 和 COVID-19 并发症的现有认识，为在 COVID-19 病毒大流行期间治疗炎症性神经眼科学疾病提供了一个框架。
